RecruitingHepatocellular Carcinoma
Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in patients with large hepatocellular carcinoma (greater than 8 cm) who maintain good liver function.
Sponsor: Seoul National University Hospital
You may qualify if…
- ✓ 1. Adults aged 18 and over.
- ✓ 2. Patients diagnosed with hepatocellular carcinoma histologically and/or radiologically (LI-RADS 4 or 5).
- ✓ 3. Patients with no more than five lesions in dynamic contrast-enhanced CT or MRI, and the largest tumor diameter exceeding 8 cm.
- ✓ 4. Patients without vascular invasion and bile duct invasion in dynamic contrast-enhanced CT or MRI.
- ✓ 5. Patients with no extrahepatic metastasis in lung CT and contrast-enhanced abdominal CT or MRI.
- ✓ 6. Patients with no prior treatment for liver cancer.
- ✓ 7. Child-Pugh class A.
- ✓ 8. ECOG performance status of 1 or less.
You may not qualify if…
- ✕ 1. Patients who are not suitable for ablative radioembolization as indicated by pre-treatment testing with macro-aggregated albumin labeled with technetium-99 (99mTc-MAA) for radioembolization.
- ✕ 1. Cases where the estimated lung dose exceeds 15 Gy when 150 Gy of absorbed dose is administered to the tumor based on the partition method.
- ✕ 2. Cases with severe hepatic artery-portal vein shunting that might lead to irradiation of the non-tumorous liver segments.
- ✕ 2. Patients whose volume of non-tumorous liver not included in the treatment area is less than 30% of the total non-tumorous liver volume.
- ✕ 3. Patients scheduled to use immunotherapy irrespective of the response to radioembolization.
- ✕ 4. Patients who have had active cancer within the last two years prior to the clinical trial participation.
- ✕ 5. Patients who have undergone surgery or procedures related to the bile duct.
- ✕ 6. Women who are pregnant or breastfeeding.
Source: ClinicalTrials.gov · NCT06178198 · last updated 2026-08-20